



Article

From Survey Results to a Decision-Making Matrix for Strategic Planning in Healthcare: The Case of Clinical Pathways

Lavinia Bianco ¹, Salvatore Raffa ^{2,3} , Paolo Fornelli ^{4,5}, Rita Mancini ^{2,3}, Angela Gabriele ⁶, Francesco Medici ⁷, Claudia Battista ⁸, Stefania Greco ⁷, Giuseppe Croce ⁹, Aldo Germani ² , Simona Petrucci ^{2,3}, Paolo Anibaldi ³, Valerio Bianco ¹⁰, Mario Ronchetti ^{4,5}, Giorgio Banchieri ^{4,5}, Christian Napoli ^{3,10} and Maria Piane ^{2,3,*}

- ¹ Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; lavinia.bianco@uniroma1.it
- ² Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, Viale Regina Elena 291, 00161 Rome, Italy; salvatore.raffa@uniroma1.it (S.R.); rita.mancini@uniroma1.it (R.M.); aldo.germani@uniroma1.it (A.G.); simona.petrucci@uniroma1.it (S.P.)
- ³ Sant’Andrea University Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy; panibaldi@ospedalesantandrea.it (P.A.); christian.napoli@uniroma1.it (C.N.)
- ⁴ Associazione Italiana per la Qualità della Assistenza Sanitaria e Sociale (ASISQUAS), Largo Konrad Adenauer 1/B, 00144 Rome, Italy; fornellip26@gmail.com (P.F.); ronchetti.mario@gmail.com (M.R.); giorgio.banchieri@gmail.com (G.B.)
- ⁵ Department of Social Sciences and Economics, “Sapienza” University of Rome, Via Salaria 113, 00198 Rome, Italy
- ⁶ Azienda Sanitaria Locale (ASL) Frosinone District C and D, Via De Bosis-03043 Cassino, Via Piemonte, 03039 Sora, Italy; angela.gabriele1@virgilio.it
- ⁷ Azienda Ospedaliera San Camillo-Forlanini, Circonvallazione Gianicolense, 87, 00152 Rome, Italy; fam.medici@mac.com (F.M.); stefaniagreco@libero.it (S.G.)
- ⁸ Department of Mental Health and Pathological Addictions, Azienda Sanitaria Locale (ASL) RM 6, Via Borgo Garibaldi 12, 00041 Albano Laziale, Italy; claudia.battista@gmail.com
- ⁹ Internal Medicine Unit, “G. Mazzini” Hospital, ASL 4 Teramo, Piazza Italia 1, 64100 Teramo, Italy; gpp.crc@me.com
- ¹⁰ Department of Medical Surgical Sciences and Translational Medicine, “Sapienza” University of Rome, Via di Grottarossa 1035/1039, 00189 Rome, Italy; valerobianco99@gmail.com
- * Correspondence: maria.piane@uniroma1.it; Tel.: +39-063-377-54-97



Citation: Bianco, L.; Raffa, S.; Fornelli, P.; Mancini, R.; Gabriele, A.; Medici, F.; Battista, C.; Greco, S.; Croce, G.; Germani, A.; et al. From Survey Results to a Decision-Making Matrix for Strategic Planning in Healthcare: The Case of Clinical Pathways. *Int. J. Environ. Res. Public Health* **2022**, *19*, 7806. <https://doi.org/10.3390/ijerph19137806>

Academic Editors: Paolo Castiglia and Marco Dettori

Received: 17 May 2022

Accepted: 21 June 2022

Published: 25 June 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Background: It is a well-known fact that the information obtained from a survey can be used in a healthcare organizational analysis; however, it is very difficult to compare the different results found in the literature to each other, even through the use of meta-analysis, as the methodology is often not consistent. Methods: Data from a survey analyzing the organizational and managerial responses adopted in pathology-specific clinical pathways (CPs) during the first two waves of the COVID-19 pandemic were used for constructing a decisional matrix, a tool called SPRIS system, consisting of four different sheets. The first sheet reports the results of the survey and, using a streetlight color system, identifies strengths and weaknesses; the second one, by assigning a priority score, establishes the priority of intervention on each of the strengths and weaknesses identified; the third sheet reports the subjective items of the questionnaire in order to identify threats and opportunities and their probability of happening; in the last sheet, a SWOT Analysis is used to calculate the performance index of the whole organization. Results: The SPRIS system, applied to data concerning the adaptation of four CPs to the COVID-19 pandemic, showed that, whereas all the CPs had a good performance index, some concerns remained unsolved and need be addressed. Conclusions: The SPRIS system showed to be an easily constructed tool that is able to give an overview of the organization analyzed by the survey and to produce an index that can be used in a direct quality comparison between different services or organizations.

Keywords: clinical pathways; comparison tool; strategic planning; COVID-19; healthcare system

1. Introduction

In face of the growing importance of evidence-based interventions (EBIs), based on the concept that decisions and interventions must use the most appropriate information and evidence [1,2], there has been an increasing trend regarding the use of quality measurement of healthcare systems [3,4]. However, in contrast to evidence-based medicine (EBM), obtaining evidence for public health policy and its quality is much more complex, as the policy process involves a series of steps whose evidence is complex to acquire. In fact, the effectiveness of interventions, feasibility of the organization, and implementation, which are less commonly covered by research evidence, are often difficult to decipher, susceptible to interpretations, and apt to be misinterpreted [5,6].

It is suggested that the best way to obtain evidence about a policy that has already been introduced is through interviews or surveys specifically designed to measure the quality of care and the policy [3,6,7]. In fact, a policy is largely a trial-and-error process, and, therefore, the scientific community can provide a crucial contribution by providing rigorous and fast evaluations of it [6]. Moreover, survey research is an important methodology, and it is considered to be the easiest way of collecting considerable information from which one can draw a meaningful conclusion in a relatively short period, sometimes with a direct economic impact [6–10].

However, interviews and survey often lack objectivity and leave too much freedom in the interpretations of the results. Even if it is believed that the intellectual rigor of EBM is applicable in this context [6], the lack of adequate data may threaten the validity of results, as complete and transparent reporting is necessary for readers to adequately assess the biases, strengths, and weaknesses of the study and the generalizability of the results [8]. In fact, if the results cannot be generalized, it can be very hard to use them as evidence when creating a new public health policy [4]. This is something that the scientific community has already highlighted as a problem, especially for patient-reported outcomes (PROs), often trying to solve it with the standardization of the scores from different instruments as standardized response means (SRMs); however, since standard deviations (SD) may vary substantially from one study to another one, treatment effects that are homogeneous when expressed in their original unit can become heterogeneous when expressed as SRMs [11].

It has been suggested, as a possible solution, to create a registry to collect all the survey research and also to regulate what sort of analysis will be carried out [10]. However, at the moment, the comparison between surveys is often made by using only the items in common; on the contrary, for the other items or for indicators based on the authors' opinion, the comparability cannot be achieved, and, therefore, it is omitted, determining the loss of any comparison [12].

Therefore, it is evident that finding a common data analysis method is a priority [10], especially to enhance the comparison across countries and over time [13]. Thus, the qualitative responses obtained from a survey should be transformed into measurable values that are able to identify and weight the strengths and weaknesses that emerge, highlighting critical issues of the organization and establishing intervention priorities to reach an adequate level of medical assistance.

Aim of the Current Study

In this scientific context, we propose a new tool, the Streetlight PRIority Swot system (SPRIS), in order to evaluate the quality of health services and to suggest improvement actions emerged by a survey. The SPRIS was subsequently applied to the results of a previously performed survey that aimed to analyze the organizational and managerial responses adopted in four pathology-specific clinical pathway (CPs) during the COVID-19 pandemic [14]. This methodology may represent a proposal model for measuring the quality of an activity (or a service) included into public health policies.

2. Materials and Methods

The COVID survey, used as starting point to be evaluated [14], consists of 37 items grouped by thematic area into eight sections. The Questionnaire Sections are as follows:

1. Context analysis;
2. Patients' access to Care Pathways (CPs)/Operational Units (OUs);
3. Impact on the treatment of non-COVID patients in the CPs;
4. Impact on the treatment of patients also SARS-CoV-2 infected in the CPs;
5. Impact of the COVID-19 pandemic on patient management;
6. Structural and organizational changes of the CPs/OUs;
7. Procedures and recommendations for healthcare professionals/users;
8. Training, information, and management of health workers in the pandemic era.

The investigated OUs belong to four different Local Health Units (ASL)/Hospitals (AO) and are divided as follows: seven OUs to the hereditary breast–ovarian cancers CP (inserted as CP1 in the SPRIS), six OUs to the autism spectrum disorders (DSA) CP (inserted as CP2), six OUs to the diabetes CP (inserted as CP3), and five OUs related to the heart failure CP (inserted as CP4) [14].

During the previous survey study, the means and standard deviations (SDs) of a bipolar 4-point Likert scales were calculated for each question of the survey (“yes” is equal to 4, “enough” to 3, “not enough” to 2, “not at all” to 1, and “not applicable” to 0) [15]. A mean score ≥ 1.80 was considered to be the cutoff for an acceptable level of performance of the CP, and a mean score ≥ 2.99 was the cutoff for a good level of performance of the CP; a mean score < 1.80 was considered as a not acceptable level of performance [14]. The methodology adopted in the survey will not be reported in detail in this paper, but it can be found in the previous article [14] and in Supplementary Material S2. In regard to the Likert scale, this is a very common method of attitude measurement in which the respondent is asked to check one of five possible answers, each one associated with a score from 0 to 4; the final results are the sum of the point values for the choices selected [15].

In the present study, the authors decided to go one step further, performing and testing the SPRIS, which includes four Microsoft Excel sheets.

This tool works as a strategic management process tool; it allows an immediate and clear view of critical areas, gives a priority score to each found criticism, and calculates a performance index through a Next-Generation SWOT Analysis, as a measure of the quality of the activity/service addressed. The tool allows a depth of data reading according to different degrees of aggregation, and it provides an answer (feedback) which can be used to evaluate the organizational performance.

In the **first sheet** (*Streetlight color system sheet*) are inserted the results of the previously cited survey [14], showing the results of each analyzed item and allowing users to recognize all the items that represented strengths (colored in green) and weaknesses (colored in yellow and red).

In the **second sheet** (*Priority scores sheet*), the mean scores of the items are classified with a graduated scale from 1 to 10, with the intention to establish how important those items are for the strategic planning and to establish the priority of each improving action.

The survey used [14] reports only objective items, those that do not investigate opportunities and threats external to the organization, whose priority scores can be used directly by themselves. In the case of surveys including subjective items, those being external, that have a probability to happen, a **third sheet** of the tool (*Delphi-like sheet*) is foreseen to analyze the probabilities that the opportunities and threats will occur. The probability is calculated with the Delphi-like method, which extrapolates for each opportunity and threat a median of the single opinions (expressed as a percentage that the event will occur) given by a team of experts; if a median cannot be calculated, the experts, after the necessary comparisons, reach a shared opinion. Since the survey that is used in this article has no subjective items [14], as there are no items regarding elements external to the CPs' inner workings, it was not necessary to apply the *Delphi-like sheet*. This does not affect the analysis of this survey, as the *Delphi-like sheet* is an extra-analysis-tool, valid only for surveys

reporting subjective items, and it can, therefore, be excluded from the analysis of surveys that lack such items. Overall, it was developed as a further support, and it can be found in Supplementary Materials S1.

Lastly, in the **fourth sheet** (NGSA sheet), strengths and weaknesses are inserted into a new type of SWOT Analysis, the Next-Generation SWOT Analysis (NGSWOT Analysis or NGSA). The classic SWOT shows an evident weakness: the four groups of elements are inserted in a descriptive way, and it is not possible to understand neither if a favorable or unfavorable picture for the implementation of a goal is produced, nor where it is necessary to take improving actions. Therefore, the NGSWOT Analysis was designed to reduce this criticism, as the insertion of the numerical values obtained for the strengths and weaknesses in SWOT allows users to correlate all data as a whole and calculate an indicator of the organization’s performance, the performance index.

The whole process is summarized in Figure 1, while the construction of the sheets is shown in Figure 2 and in Supplementary Materials S1.




Figure 1. Workflow chart. The gray squares indicate the methodology of the first study published by the authors [14].




Figure 2. Graphic representation of the construction of the Excel sheets of SPRIS and the meaning of each one of them.

2.1. First Sheet: Streetlight Color System

The objective of this first sheet is to photograph a complete picture, by successive levels of aggregation, of the reality that is being investigated. The tool is able to evaluate the parameters entered and identify, both horizontally (at the parameter level) and vertically (at the organizational level), the most critical areas of the organization/department/operational units being analyzed.

Using the already established cutoffs [14], we created a graphic model with three different colors, namely green, yellow, and red, a so-called “streetlight color system”, thanks to Excel Conditional Formatting; it allows a synoptic and immediate reading of the results. The three colors highlight the structures on which an improvement intervention is necessary. In this way, it is clear from just a glance that the areas that already have a good level of performance are colored in green; the ones that are adequate but can be modified to achieve better results are colored in yellow; and, lastly, the ones that need immediate corrections are colored in red (critical areas) (Figure 3). Since both red and yellow have issues that need to be addressed, we classified them as strong and faint weaknesses, respectively, while green was classified as strength.

2.2. Second Sheet: Priority Scores

The streetlight color system only highlights strengths and weaknesses but does not organize them and does not give them a priority, which is the feature needed when constructing a decisional matrix. Therefore, once that the streetlight color system was created, it was deemed necessary to give each of the found weakness and strength a priority of intervention through a classification scale. In order to fulfill this sheet, a panel of experts is necessary. The panel must be composed by at least three components: one expert in healthcare services evaluation, one expert in public health, and one expert in healthcare services management. The items with the lowest scores are the ones that have to be addressed first in the decision matrix.

Figure 3. Example of SPRI application. Photograph of the complete picture given by the *Streetlight color system* sheet, showing the first three Questionnaire Sections of the questionnaire for two CPs.

The actions to improve the quality of an analyzed service can be organized with a timing that depends on the priority obtained (priority score) from the classification scale.

2.2.1. Classification Scale

The cutoffs for each group of the classification scale are generate by dividing the main interval into ten sub-intervals of similar “length” that are then classified in a scale from 1 to 10, with weaknesses going from 1 to 7 and strengths from 8 to 10 (Table 1). In our case, the length of each sub-interval is about 0.4, as the questionnaire we bring as an example has a scoring system from 0 to 4, but the system can be applied to any range. For instance, if the questionnaire had a scoring system from 0 to 20, the 10 sub-intervals would be about 2 points each, and the three main intervals about 6.7 points each.

Table 1. Comparison between the established cutoffs and the sub-intervals. The established cutoffs allow the synoptic reading of the first Excel sheet (*streetlight color system*), while the sub-intervals allow us to give the classification scale group.

<i>Established Cutoffs [1]</i>	<i>Sub-Intervals</i>	<i>Color</i>	<i>Category</i>	<i>Classification Scale</i>
Not Acceptable < 1.80	<0.45	Red	Strong Weakness	1
	0.46–0.89	Red	Strong Weakness	2
	0.90–1.35	Red	Strong Weakness	3
	1.36–1.79	Red	Strong Weakness	4
1.80 ≤ Acceptable ≤ 2.98	1.80–2.20	Yellow	Faint Weakness	5
	2.21–2.60	Yellow	Faint Weakness	6
	2.61–2.98	Yellow	Faint Weakness	7
Good ≥ 2.99	2.99–3.33	Green	Strength	8
	3.34–3.66	Green	Strength	9
	3.67–4.00	Green	Strength	10

To summarize, the main cutoffs allow the synoptic reading of the *Streetlight color system* sheet, while the sub-intervals allow to give the priority score.

2.2.2. Conversion Scale

To insert in the NGSWOT Analysis the correct “weight” for each item, we established a conversion scale, so that, for each cutoff, there is a corresponding score that is different for strong weaknesses, faint weaknesses, and strengths. This is necessary, as the classification scale by itself gives the order of importance but not a score that can be inserted into a SWOT Analysis.

Weaknesses have a descending consecutive scoring system (as the items with the lowest classification scale number are more “important”): from 5 to 2 for strong weaknesses, and from 1.5 to 0.5 for faint weaknesses. In order to differentiate between strong and faint weaknesses, the former would have a scoring system by one point and the latter by half a point.

The strengths, instead, have an increasing consecutive scoring system by 1.5 points, from 1.5 to 4.5; it is used a system by 1.5 points to compensate for the fact that the value of all the weaknesses, especially the strong weaknesses, should be balanced by the strengths found in the same setting, while still highlighting the critical areas. Therefore, the strength with the highest priority score should be about 0.5 points lower than the strong weakness with the highest priority score; at the same time, the strength with the lowest priority score should be able to compensate for only the faint weaknesses and nothing higher. In other words, the classification n.8 had to have a priority score of 1.5 (equal to classification 5), and the classification n.10 had to have a priority score of 4.5 (0.5 lower than classification 1); from there, the 1.5 system was an obvious conclusion (Table 2).

Table 2. Conversion table. Weaknesses have a descending consecutive scoring system, from 5 to 2 for strong weaknesses, and from 1.5 to 0.5 for faint weaknesses, and strengths have an increasing consecutive scoring system from 1.5 to 4.5. The priority score is to be inserted into the NGSWOT. The category is colored depending on the streetlight color system.

Classification Scale	Priority Score	Category
1	5	Strong Weakness
2	4	Strong Weakness
3	3	Strong Weakness
4	2	Strong Weakness
5	1.5	Faint Weakness
6	1	Faint Weakness
7	0.5	Faint Weakness
8	1.5	Strength
9	3	Strength
10	4.5	Strength

This priority scores so obtained are reported in the *Priority scores* sheet (Figure 4), alongside the mean score they are referring to and the category they belong to (strength and strong or faint weakness).

2.3. Last Sheet: Next-Generation SWOT Analysis

The NGSWOT calculates a performance index, which is a measure of the quality and of the level of performance that is shown by the activity/service analyzed with the survey, which, in this specific case, is how well—or how badly—the four chosen clinical pathways adjusted to the COVID-19 pandemic.

Based on the value of the calculated index, it can be decided whether it is useful to spend resources into that activity/service. In case of a low performance index, the whole process must be repeated after having acted upon the weaknesses of the chosen activity to have proof that the improvement actions are actually working.

The NGSWOT is constructed as follows: a first table for the strengths and their scores, a second table for the weaknesses (both strong and faint) and their scores, and two more tables for opportunities and threats and their weighted scores (Figure 5A).

ALL SUBJECTS										
Subject 1										
ITEMS	TOTAL MEAN SCORE	Classification scale	PRIORITY SCORE	Category	MEAN SCORE	Classification scale	PRIORITY SCORE	Category	MEAN SCORE	
SECTION 1	item 1	2.54	6	1.0	Faint Weakness	Insert score	#N/D	#N/D	#N/D	Insert score
	item 2	2.21	6	1.0	Faint Weakness	Insert score	#N/D	#N/D	#N/D	Insert score
	item 3	3.38	9	3.0	Strength	Insert score	#N/D	#N/D	#N/D	Insert score
	item 4	2.50	6	1.0	Faint Weakness	Insert score	#N/D	#N/D	#N/D	Insert score
	item 5	3.38	9	3.0	Strength	Insert score	#N/D	#N/D		Insert score
	item 6	2.50	6	1.0	Faint Weakness	Insert score	#N/D	#N/D		Insert score
SECTION 1 MEAN SCORE		2.66	7	0.5	Faint Weakness	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
		Insert score	#N/D	#N/D	#N/D	Insert score	#N/D	#N/D	#N/D	Insert score
		Insert score	#N/D	#N/D	#N/D	Insert score	#N/D	#N/D	#N/D	Insert score
		Insert score	#N/D	#N/D	#N/D	Insert score	#N/D	#N/D	#N/D	Insert score
		Insert score	#N/D	#N/D	#N/D	Insert score	#N/D	#N/D	#N/D	Insert score
		Insert score	#N/D	#N/D	#N/D	Insert score	#N/D	#N/D	#N/D	Insert score
		Insert score	#N/D	#N/D	#N/D	Insert score	#N/D	#N/D	#N/D	Insert score

Figure 4. Example of *Priority scores* sheet of SPRIS; for each mean score, we report the correspondent classification scale, the priority score, and the category, following the conversion table. The construction of this second Excel sheet depends on the level of depth of the organizational analysis that is being applied. The analysis can be carried out at different levels: macro-dimensional, if one chooses to insert the data (mean scores) concerning the CP as a whole, with both horizontal and vertical reading; or micro-dimensional, if one chooses to insert the mean scores for individual items, using only the horizontal or only the vertical.

The first two tables are compiled by inserting the scores reported in the second Excel sheet (*Priority scores* sheet), depending on the category the item belongs to. The last two tables are compiled by inserting the scores reported in the *Priority scores* sheet and the probabilities reported in the *Delphi-like* sheet; the weighted score is calculated directly by these last two tables, multiplying the priority score of that item for the probability calculated through the Delphi-like method.

As previously stated, in the survey that we bring as an example [14], all the items of the questionnaire are about objective data, intending with this term all those items that do not investigate opportunities and threats external to the organization. In this case, the priority scores can be used as they are, as there is no probability of the event occurring that must be considered. Therefore, it was not necessary to include these last two tables or the process connected to their application.

2.3.1. Performance Index

The NGSAs use the sum of both the priority scores (strength and weakness) and the weighted scores (opportunities and threats) to calculate a performance index, which is a percentage ratio that is calculated by using the following formula:

$$\frac{(\text{strength} + \text{opportunity}) * 100\%}{((\text{strength} + \text{opportunity}) + (\text{weakness} + \text{threat}))}$$

Therefore, the Next-Generation SWOT Analysis differentiates itself from other SWOT Analyses, as it is not only a descriptive method but also an objective analysis system.

In our specific case, it was not necessary to include opportunities and threats in the formula for the performance index:

$$\frac{\text{strength} * 100\%}{(\text{strength} + \text{weakness})}$$

- High if between the second and the third quartile;
- Very high if between the third and the fourth quartile.

2.4. COVID Survey and SPRISS

The COVID survey, used as an organizational analysis tool, consists of 37 items grouped by thematic area into eight sections (Questionnaire Sections); all the Questionnaire Sections and the single items of the survey are included in the first Excel sheet (*Streetlight color system sheet*), following the order established in the questionnaire [14]. For each question, we report the Likert scale value correspondent to the qualitative answers given by each operational unit/ward responding to the survey, assembled depending on the CP they belong to (Figure 6A). Thanks to the colors provided with the cutoffs, the reading is both immediate and multidimensional, as it can be read both horizontally and vertically: horizontally, we can find the data about the single question and the Questionnaire Section of the questionnaire; and vertically, the data about each CP and each OU/ward are reported. (Figure 6B).

(A)

		DS question - ALLCPs	mean score question - ALL CPs	mean score question - CP 1	Clinical Pathway 1						
					Ward 1	Ward 2	Ward 3	Ward 4	Ward 5	Ward 6	Ward 7
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	4.12	3.00	2.86	3.00	4.00	2.00	3.00	1.00	3.00	4.00
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	3.32	3.14	2.57	2.00	3.00	1.00	3.00	2.00	3.00	4.00
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	4.77	4.85	3.77	4.00	4.00	4.00	4.00	2.00	4.00	4.00
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	3.60	3.50	2.86	3.00	3.00	1.00	4.00	1.00	4.00	4.00
MEAN SCORE					3.00	3.50	2.00	3.50	1.50	3.50	4.00
STANDARD DEVIATION					0.71	0.50	1.22	0.50	0.50	0.50	0.00
CP MEAN SCORE FOR THIS SECTION				3.00							

(B)

Figure 6. Cont.

		mean score	Clinical Pathway 2					
		question - CP	Ward 1	Ward 2	Ward 3	Ward 4	Ward 5	Ward 6
IMPACT ON TAKING OVER THE CP OF PATIENTS ALSO SARS-INFECTED	Have you treated COVID + patients in the pathway CP/UO?	1.0	1.0	1.00	1.00	1.00	1.00	1.00
	If yes or enough: in hospital in COVID wards?	0.33	0.00	0.00	1.00	0.00	0.00	1.00
	If yes or enough: by telephone counselling in COVID wards?	0.33	0.00	0.00	1.00	0.00	0.00	1.00
	If yes or enough: other	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	2.17	0.00	0.00	1.00	4.00	4.00	4.00
	MEAN SCORE			0.20	0.20	0.80	1.00	1.00
STANDARD DEVIATION			0.40	0.40	0.40	1.55	1.55	1.55
CP MEAN SCORE FOR THIS SECTION	0.77							
CP STANDARD DEVIATION FOR THIS SECTION	0.38							

(C)

Figure 6. Example of SPRIS (Streetlight PRLority Swot) application. (A) Photograph of the complete picture given by the *Streetlight color system* sheet, showing the first three Questionnaire Sections for two of the considered CPs. (B) Extraction of the first Questionnaire Section of the first CP. We can read the data about each item/ward (answer score in related cell; the gray circle shows as an example the score of item 1 reached by Ward 3) or about each item/CP (mean score of the answers of a single item for the CP as a whole, shown as an example for item 4 by the purple circle), or about each item/total CPs (mean score of the answers regarding a single item for all the CPs, shown as an example for item 2 by the light blue circle); for each Questionnaire Section of each CP a mean score is calculated (pink circle). (C) Extraction of the fourth Questionnaire Section of the second CP. Horizontally, we can find the data about the single question (neon green rectangle) and the fourth Questionnaire Section (blue rectangle); vertically, the data about one specific CP (dark green circle) and one of the first OU/wards (orange rectangle) are reported.

In the second Excel sheet (*Priority scores* sheet), after having applied the conversion scale (Table 2) to identify the correct priority score of each item of every CP (Figure 7A), it is possible to group and separate the results for each CP (Figure 7B); for each OU/ward (Figure 7C); for each item, regardless of the CP or the OU/ward (Figure 7D); and, lastly, for each Questionnaire Section, regardless not only of the CP or the OU/ward (Figure 7E). The last method might be useful if the analysis must be quickly performed, even if it gives only a superficial overview. In a second moment, for instance, if a Questionnaire Section is categorized as weakness, a more detailed analysis can be added.

The results so grouped are then inserted into the last Excel sheet (*NGSA* sheet), constructed with the four tables, as shown in Figure 5A, plus an additional square that reports the total sum of the priority scores for every category (strengths, weaknesses, opportunities, and threats) and the performance index that has been calculated for each chosen depth of analysis (Figure 5B). However, seeing that there are not subjective items, the last two tables have not been filled; therefore, the NGSA sheets all appear similar to the one shown in Figure 8.

	ITEMS	All CPs				CP 1				CP 2				CP 3				CP 4			
		TOTAL MEAN SCORE	Classification scale	PRIORITY SCORE	Category	CP 1 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category	CP 2 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category	CP 3 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category	CP 4 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	2.54	6	1.0	Faint Weakness	2.86	7	0.5	Faint Weakness	3.67	10	4.5	Strength	1.00	3	3.0	Strong Weakness	2.60	6	1.0	Faint Weakness
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.21	6	1.0	Faint Weakness	2.57	6	1.0	Faint Weakness	2.83	7	0.5	Faint Weakness	1.00	3	3.0	Strong Weakness	2.40	6	1.0	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	3.38	9	3.0	Strength	3.71	10	4.5	Strength	2.83	7	0.5	Faint Weakness	4.00	10	4.5	Strength	2.80	7	0.5	Faint Weakness
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	2.50	6	1.0	Faint Weakness	2.86	7	0.5	Faint Weakness	2.17	5	1.5	Faint Weakness	3.00	8	1.5	Strength	1.80	5	1.5	Faint Weakness
	SECTION 1 MEAN SCORE	2.63	7	0.5	Faint Weakness	3.00	8	1.5	Strength	2.88	7	0.5	Faint Weakness	2.25	6	1.0	Faint Weakness	2.40	6	1.0	Faint Weakness
PATIENTS ACCESS TO CP/LOD	Do you use a pre-triage module during treatment?	3.46	9	3.0	Strength	3.00	8	1.5	Strength	4.00	10	4.5	Strength	4.00	10	4.5	Strength	2.80	7	0.5	Faint Weakness
	Are security measures taken?	3.92	10	4.5	Strength	4.00	10	4.5	Strength	4.00	10	4.5	Strength	4.00	10	4.5	Strength	3.60	9	3.0	Strength
	Are social distancing measures taken?	3.71	10	4.5	Strength	3.86	10	4.5	Strength	3.67	10	4.5	Strength	4.00	10	4.5	Strength	3.20	8	1.5	Strength
	SECTION 2 MEAN SCORE	3.68	10	4.5	Strength	3.62	9	3.0	Strength	3.89	10	4.5	Strength	4.00	10	4.5	Strength	3.20	8	1.5	Strength
	Has patient taking over been guaranteed within the pathway care anyway?	3.42	9	3.0	Strength	3.86	10	4.5	Strength	3.83	10	4.5	Strength	2.50	6	1.0	Faint Weakness	3.40	9	3.0	Strength
IMPACT ON TAKING OVER IN THE FOR OF NO-COVID PATIENTS	Have the cancelled visits been rescheduled and recovered?	2.88	7	0.5	Faint Weakness	3.86	10	4.5	Strength	2.33	6	1.0	Faint Weakness	3.33	8	1.5	Strength	1.60	4	2.0	Strong Weakness
	Has remote monitoring been activated for patients who could not interrupt the treatment path (telemedicine)?	2.25	6	1.0	Faint Weakness	2.57	6	1.0	Faint Weakness	1.67	4	2.0	Strong Weakness	2.83	7	0.5	Faint Weakness	1.80	5	1.5	Faint Weakness
	SECTION 3 MEAN SCORE	2.80	7	0.5	Faint Weakness	3.43	9	3.0	Strength	2.61	7	0.5	Faint Weakness	2.89	7	0.5	Faint Weakness	2.27	6	1.0	Faint Weakness
	Have you treated COVID + patients in the pathway CP/LOD?	1.04	3	3.0	Strong Weakness	0.86	2	4.0	Strong Weakness	1.00	3	3.0	Strong Weakness	1.17	3	3.0	Strong Weakness	1.20	3	3.0	Strong Weakness
	If yes or enough: in hospital in COVID wards?	0.21	1	5.0	Strong Weakness	0.29	1	5.0	Strong Weakness	0.33	1	5.0	Strong Weakness	0.17	1	5.0	Strong Weakness	0.00	1	5.0	Strong Weakness
IMPACT ON TAKING OVER IN THE FOR OF INFECTED PATIENTS ALSO SARS-COV-2	If yes or enough: by telephone counselling in COVID wards?	0.29	1	5.0	Strong Weakness	0.29	1	5.0	Strong Weakness	0.33	1	5.0	Strong Weakness	0.50	2	4.0	Strong Weakness	0.00	1	5.0	Strong Weakness
	If yes or enough: other	0.17	1	5.0	Strong Weakness	0.29	1	5.0	Strong Weakness	0.00	1	5.0	Strong Weakness	0.33	1	5.0	Strong Weakness	0.00	1	5.0	Strong Weakness
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	2.21	6	1.0	Faint Weakness	2.43	6	1.0	Faint Weakness	2.17	5	1.5	Faint Weakness	1.17	3	3.0	Strong Weakness	3.20	8	1.5	Strength
	SECTION 4 MEAN SCORE	2.21	6	1.0	Faint Weakness	2.43	6	1.0	Faint Weakness	2.17	5	1.5	Faint Weakness	1.17	3	3.0	Strong Weakness	3.20	8	1.5	Strength
	SECTION 5 MEAN SCORE	2.21	6	1.0	Faint Weakness	2.43	6	1.0	Faint Weakness	2.17	5	1.5	Faint Weakness	1.17	3	3.0	Strong Weakness	3.20	8	1.5	Strength

(A)

	ITEMS	CP 1			
		CP 1 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	2.86	7	0.5	Faint Weakness
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.57	6	1.0	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	3.71	10	4.5	Strength
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	2.86	7	0.5	Faint Weakness
	SECTION 1 MEAN SCORE	3.00	8	1.5	Strength

(B)

	ITEMS	Ward 1 CP 1			
		SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	3.00	8	1.5	Strength
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.00	5	1.5	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	4.00	10	4.5	Strength
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	3.00	8	1.5	Strength
	SECTION 1 MEAN SCORE	3.00	8	1.5	Strength

(C)

	ITEMS	All CPs			
		TOTAL MEAN SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	2.54	6	1.0	Faint Weakness
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.21	6	1.0	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	3.38	9	3.0	Strength
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	2.50	6	1.0	Faint Weakness
	SECTION 1 MEAN SCORE	2.63	7	0.5	Faint Weakness
	SECTION 2 MEAN SCORE	3.68	10	4.5	Strength
	SECTION 3 MEAN SCORE	2.80	7	0.5	Faint Weakness
	SECTION 4 MEAN SCORE	0.79	2	4.0	Strong Weakness

(D)

	ITEMS	All CPs			
		TOTAL MEAN SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	SECTION 1 MEAN SCORE	2.63	7	0.5	Faint Weakness
	SECTION 2 MEAN SCORE	3.68	10	4.5	Strength
	SECTION 3 MEAN SCORE	2.80	7	0.5	Faint Weakness
	SECTION 4 MEAN SCORE	0.79	2	4.0	Strong Weakness
	SECTION 5 MEAN SCORE	3.09	8	1.5	Strength
	SECTION 6 MEAN SCORE	3.10	8	1.5	Strength
	SECTION 7 MEAN SCORE	3.63	9	3.0	Strength
	SECTION 8 MEAN SCORE	3.19	8	1.5	Strength

(E)

Figure 7. (A) Photograph of the Priority scores sheet of SPRIS; for each mean score, we report the correspondent classification scale, the priority score, and the category, following the conversion table. (B) Extraction of the Priority scores sheet regarding the first Questionnaire Section of the survey referring to the first CP considered. (C) Extraction regarding the first ward considered (vertical reading of the streetlight color system). (D) Extraction regarding the items of the first Questionnaire Section (horizontal reading of the Streetlight color system). (E) Extraction regarding all eight Questionnaire Sections (horizontal reading of the streetlight color system).






Figure 8. Extraction of the last Excel sheet of SPRIS (NGSA). It shows the NGSWOT Analysis compiled by using the priority scores of each item, regardless of the CP or the OU/ward, and the performance index calculated with them.

It is possible to obtain two different performance indexes, one by inserting in the NGSa the priority scores of the items and the other by using the Questionnaire Sections, regardless of the CP or the OU/ward (Figure 9). The same was performed for each CP, obtaining for each CP two different performance indexes, one by inserting in the NGSa the priority scores of the items (deeper analysis) and the other by using the Questionnaire Sections (shallower analysis).



(A)



(B)

Figure 9. Performance index calculated by using the scores of all four CPs but inserting either the single items (A) or only the Questionnaire Sections mean scores (B).

We then chose, for each CP, one OU/ward, and we report the results of every item and Questionnaire Section, obtaining, for each of the four chosen OU/wards, two different

performance indexes, one by inserting in the NGSAs the priority scores of all the items and the other by using only the mean scores of the Questionnaire Sections.

3. Results

The results regarding all four CPs are shown in Figure 10, while the results regarding each of the four chosen OU/wards are shown in Figure 11.




Figure 10. Performance indexes calculated for each CP, using the mean scores of every item of the questionnaire (A–D) and using the mean scores of every Questionnaire Section (E–H). For CP1, the deeper analysis is shown in (A), and the shallower one is in (E); for CP2, the deeper analysis is shown in (B), and the shallower one is in (F); for CP3, the deeper analysis is shown in (C), and the shallower one is in (G); lastly, for CP4, the deeper analysis is shown in (D), and the shallower one is in (H).




Figure 11. Cont.




Figure 11. Performance indexes calculated for one randomly chosen OU/ward for each CP, using the mean scores of every item of the questionnaire (A,C,E,G) and using the mean scores of every Questionnaire Section (B,D,F,H). For Ward 1 of CP1, the deeper analysis is shown in (A) and the shallower one in (B); for Ward 2 of CP2, the deeper analysis is shown in (C) and the shallower one in (D); for Ward 3 of CP3, the deeper analysis is shown in (E) and the shallower one in (F); lastly, for Ward 4 of CP4, the deeper analysis is shown in (G) and the shallower one in (H).

The performance indexes obtained with the NGSAs were distributed in ascending order to generate two curves, one regarding the items and one regarding the Questionnaire Sections.

The curve regarding the items has a mean of 62.83% and a standard deviation of 0.28, whereas the curve regarding the Questionnaire Sections has a mean of 69.61% and a standard deviation of 0.38.

It was therefore possible to establish that the index is as follows:

- For the items:
 - Null if below <52.79% (tenth percentile);
 - Low if between 52.80% and 57.55% (between the tenth percentile and the first quartile);
 - Good if between 57.56% and 62.83% (between the first and the second quartile);
 - High if between 62.84% and 68.12% (between the second and the third quartile);
 - Very high if between 68.13% and 100% (between the third and the fourth quartile).
- For the Questionnaire Sections:
 - Null if below <51.20% (tenth percentile);
 - Low if between 51.21% and 59.92% (between the tenth percentile and the first quartile);
 - Good if between 59.93% and 69.61% (between the first and the second quartile);
 - High if between 69.62% and 79.30% (between the second and the third quartile);
 - Very high if between 79.31% and 100% (between the third and the fourth quartile).

The range reached by each calculated performance index and whether it refers to the items or to the Questionnaire Sections are summarized in Table 3.

3.1. All CPs

Looking at Figure 9, it is possible to notice that the index is “very high” in the deeper analysis and “high” in the shallower one, as it is 72.9% (Figure 9A) and 70.6% (Figure 9B), respectively.

Figures 12 and 13 report the mean scores obtained with the survey, the priority scores inserted into the NGSAs, and the category.

Table 3. Summary of the results regarding the performance indexes and their corresponding ranges.

Performance Index	Subject Analyzed	Subject Name in SPRIS	Kind of Data	Range
72.9%	All CPs	All CPs	Items	Very high
70.6%	All CPs	All CPs	Questionnaire Sections	High
72.9%	Hereditary breast-ovarian cancers CP	CP 1	Items	Very high
84.9%	Hereditary breast-ovarian cancers CP	CP 1	Questionnaire Sections	Very high
61.9%	Autism spectrum disorders (DSA) CP	CP 2	Items	Good
63.6%	Autism spectrum disorders (DSA) CP	CP 2	Questionnaire Sections	Good
62.0%	Diabetes CP	CP 3	Items	Good
66.7%	Diabetes CP	CP 3	Questionnaire Sections	Good
52.6%	Heart failure CP	CP 4	Items	Null
37.5%	Heart failure CP	CP 4	Questionnaire Sections	Null
68.6%	UOC Medical Genetics	Ward 1 CP 1	Items	Very high
83.6%	UOC Medical Genetics	Ward 1 CP 1	Questionnaire Sections	Very high
51.0%	UOC Mental Health Center H1-H3	Ward 2 CP 2	Items	Null
65.2%	UOC Mental Health Center H1-H3	Ward 2 CP 2	Questionnaire Sections	Good
60.0%	UOS Primary Care District C and D	Ward 3 CP 3	Items	Good
75.0%	UOS Primary Care District C and D	Ward 3 CP 3	Questionnaire Sections	High
63.6%	UOD Shock and Trauma	Ward 4 CP 4	Items	High
79.4%	UOD Shock and Trauma	Ward 4 CP 4	Questionnaire Sections	Very high

ITEMS	All CPs		
	TOTAL MEAN SCORE	PRIORITY SCORE	Category
SECTION 1 MEAN SCORE	2.63	0.5	Faint Weakness
SECTION 2 MEAN SCORE	3.68	4.5	Strength
SECTION 3 MEAN SCORE	2.80	0.5	Faint Weakness
SECTION 4 MEAN SCORE	0.79	4.0	Strong Weakness
SECTION 5 MEAN SCORE	3.09	1.5	Strength
SECTION 6 MEAN SCORE	3.10	1.5	Strength
SECTION 7 MEAN SCORE	3.63	3.0	Strength
SECTION 8 MEAN SCORE	3.19	1.5	Strength

Figure 12. Summary of the results regarding all the Questionnaire Sections of all the CPs together.

	ITEMS	All CPs		
		TOTAL MEAN SCORE	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	2.54	1.0	Faint Weakness
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.21	1.0	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	3.38	3.0	Strength
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	2.50	1.0	Faint Weakness
PATIENTS ACCESS TO CP/ UO	Do you use a pre-triage module during treatment?	3.46	3.0	Strength
	Are security measures taken?	3.92	4.5	Strength
	Are social distancing measures taken?	3.71	4.5	Strength
IMPACT ON TAKING OVER IN THE FOR OF NO-COVID PATIENTS	Has patient taking over been guaranteed within the pathway care anyway?	3.42	3.0	Strength
	Have the cancelled visits been rescheduled and recovered?	2.88	0.5	Faint Weakness
	Has remote monitoring been activated for patients who could not interrupt the treatment path (telemedicine)?	2.25	1.0	Faint Weakness
IMPACT ON TAKING OVER IN THE CP OF PATIENTS ALSO SARS COV-2 INFECTED	Have you treated COVID + patients in the pathway CP/UO?	1.04	3.0	Strong Weakness
	If yes or enough: in hospital in COVID wards?	0.21	5.0	Strong Weakness
	If yes or enough: by telephone counselling in COVID wards?	0.29	5.0	Strong Weakness
	If yes or enough: other	0.17	5.0	Strong Weakness
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	2.21	1.0	Faint Weakness
IMPACT OF THE COVID-19 PANDEMIC ON PATIENT MANAGEMENT	Have ad hoc organizational solutions been implemented for patient management with respect to the pre-pandemic era?	3.79	4.5	Strength
	Has therapeutic continuity been ensured within the pathway care?	3.83	4.5	Strength
	Have tele-assistance technological solutions been adopted for patient follow-up?	2.25	1.0	Faint Weakness
	Did all hospitalized patients repeat the SARS-Cov-2 test several times during the hospitalization period?	1.96	1.5	Faint Weakness
	Has the correct use of PPE (personal protective equipment) by healthcare professionals and patients been monitored?	3.71	4.5	Strength
STRUCTURAL AND ORGANIZATIONAL CHANGES OF THE CP/ UO	Has the CP/UO remained unchanged from an organizational point of view?	3.00	1.5	Strength
	Have outpatient and/or surgical activities been guaranteed?	3.13	1.5	Strength
	Have the timing for the transition of a patient from one care setting to another within the CP/ UO been respected?	2.79	0.5	Faint Weakness
	Have there been multidisciplinary discussions about the patients' health conditions?	2.92	0.5	Faint Weakness
	Have structural changes been made to encourage social distancing?	3.46	3.0	Strength
	Have the services relating to non-deferrable diseases been guaranteed?	3.63	3.0	Strength
PROCEDURES AND RECOMMENDATIONS FOR HEALTHCARE	Have patient recommendations been made clear and visible?	3.79	4.5	Strength
	If yes, or enough, have they been respected?	3.54	3.0	Strength
	Have recommendations for relatives been made clear and visible?	3.83	4.5	Strength
	If yes, or enough, have they been respected?	3.58	3.0	Strength
	Have the recommendations been made clear and visible to healthcare professionals?	3.67	4.5	Strength
	If yes, or enough, have they been respected?	3.50	3.0	Strength
TRAINING, INFORMATION AND MANAGEMENT OF HEALTH WORKERS IN THE PANDEMIC ERA	Health care workers involved in PDTAs/UO have been trained on the dressing-doffing PPE procedures?	3.63	3.0	Strength
	The exposed health care personnel have been periodically subjected to rhino-pharyngeal swab to evaluate the possible positivity for SARS-CoV-2?	3.75	4.5	Strength
	Has the staff been equipped with PPE of modulated efficiency with respect to the professional risk to which they have been exposed?	3.67	4.5	Strength
	Have dirty paths and clean access paths to clinical departments been organized?	2.04	1.5	Faint Weakness
	Has the corporate anti-COVID vaccination program been performed using the employee booking portal?	2.79	0.5	Faint Weakness
	Was the anti-COVID19 vaccination campaign, in the company/facility, preceded by an information campaign on the technical characteristics, methods of setting up and administering the vaccine?	3.42	3.0	Strength

Figure 13. Summary of the results regarding all the items of all the CPs together.

Both figures (Figures 12 and 13) show that Questionnaire Section 4 (“Impact on taking over in the CP of patients also SARS-CoV-2 infected”) is the one that is identified as strong weakness.

Figure 12 also highlights how Questionnaire Section 1 (“Context Analysis”) and Questionnaire Section 3 (“Impact on the treatment of non-COVID patients in the CPs”) are both identified as faint weaknesses.

3.2. Single CPs

The results are shown in Figure 10, while Figures 14 and 15 report the mean scores obtained with the survey, the priority scores inserted into the NGSAs, and the category.

ITEMS	CP 1			CP 2			CP 3			CP 4		
	CP 1 - MEAN SCORE	PRIORITY SCORE	Category	CP 2 - MEAN SCORE	PRIORITY SCORE	Category	CP 3 - MEAN SCORE	PRIORITY SCORE	Category	CP 4 - MEAN SCORE	PRIORITY SCORE	Category
SECTION 1 MEAN SCORE	3.00	1.5	Strength	2.88	0.5	Faint Weakness	2.25	1.0	Faint Weakness	2.40	1.0	Faint Weakness
SECTION 2 MEAN SCORE	3.62	3.0	Strength	3.89	4.5	Strength	4.00	4.5	Strength	3.20	1.5	Strength
SECTION 3 MEAN SCORE	3.43	3.0	Strength	2.61	0.5	Faint Weakness	2.89	0.5	Faint Weakness	2.27	1.0	Faint Weakness
SECTION 4 MEAN SCORE	0.83	4.0	Strong Weakness	0.77	4.0	Strong Weakness	0.67	4.0	Strong Weakness	0.88	4.0	Strong Weakness
SECTION 5 MEAN SCORE	3.34	3.0	Strength	3.27	1.5	Strength	2.90	0.5	Faint Weakness	2.84	0.5	Faint Weakness
SECTION 6 MEAN SCORE	3.64	3.0	Strength	3.19	1.5	Strength	3.19	1.5	Strength	2.37	1.0	Faint Weakness
SECTION 7 MEAN SCORE	3.81	4.5	Strength	3.53	3.0	Strength	3.97	4.5	Strength	3.20	1.5	Strength
SECTION 8 MEAN SCORE	3.88	4.5	Strength	2.36	1.0	Faint Weakness	3.31	1.5	Strength	3.20	1.5	Strength

Figure 14. Summary of the results regarding all the Questionnaire Sections of the four analyzed CPs.

A	ITEMS	CP 1				CP 2			
		CP 1 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category	CP 2 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	2.86	7	0.5	Faint Weakness	3.67	10	4.5	Strength
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.57	6	1.0	Faint Weakness	2.83	7	0.5	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	3.71	10	4.5	Strength	2.83	7	0.5	Faint Weakness
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	2.86	7	0.5	Faint Weakness	2.17	5	1.5	Faint Weakness
PATIENTS ACCESS TO CP/ UO	Do you use a pre-triage module during treatment?	3.00	8	1.5	Strength	4.00	10	4.5	Strength
	Are security measures taken?	4.00	10	4.5	Strength	4.00	10	4.5	Strength
	Are social distancing measures taken?	3.86	10	4.5	Strength	3.67	10	4.5	Strength
IMPACT ON TAKING OVER IN THE FOR OF NO-COVID PATIENTS	Has patient taking over been guaranteed within the pathway care anyway?	3.86	10	4.5	Strength	3.83	10	4.5	Strength
	Have the cancelled visits been rescheduled and recovered?	3.86	10	4.5	Strength	2.33	6	1.0	Faint Weakness
	Has remote monitoring been activated for patients who could not interrupt the treatment path (telemedicine)?	2.57	6	1.0	Faint Weakness	1.67	4	2.0	Strong Weakness

Figure 15. Cont.

IMPACT ON TAKING OVER IN THE CP OF PATIENTS ALSO SARS COV-2 INFECTED	Have you treated COVID + patients in the pathway CP/VO?	0.86	2	4.0	Strong Weakness	1.00	3	3.0	Strong Weakness
	If yes or enough: in hospital in COVID wards?	0.29	1	5.0	Strong Weakness	0.33	1	5.0	Strong Weakness
	If yes or enough: by telephone counselling in COVID wards?	0.29	1	5.0	Strong Weakness	0.33	1	5.0	Strong Weakness
	If yes or enough: other	0.29	1	5.0	Strong Weakness	0.00	1	5.0	Strong Weakness
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	2.43	6	1.0	Faint Weakness	2.17	5	1.5	Faint Weakness
IMPACT OF THE COVID-19 PANDEMIC ON PATIENT MANAGEMENT	Have ad hoc organizational solutions been implemented for patient management with respect to the pre-pandemic era?	4.00	10	4.5	Strength	3.83	10	4.5	Strength
	Has therapeutic continuity been ensured within the pathway care?	4.00	10	4.5	Strength	3.83	10	4.5	Strength
	Have tele-assistance technological solutions been adopted for patient follow-up?	1.86	5	1.5	Faint Weakness	3.00	8	1.5	Strength
	Did all hospitalized patients repeat the SARS-Cov-2 test several times during the hospitalization period?	3.43	9	3.0	Strength	1.67	4	2.0	Strong Weakness
	Has the correct use of PPE (personal protective equipment) by healthcare professionals and patients been monitored?	3.43	9	3.0	Strength	4.00	10	4.5	Strength
STRUCTURAL AND ORGANIZATIONAL CHANGES OF THE CP/VO	Has the CP/VO remained unchanged from an organizational point of view?	3.43	9	3.0	Strength	2.67	7	0.5	Faint Weakness
	Have outpatient and/or surgical activities been guaranteed?	3.71	10	4.5	Strength	3.00	8	1.5	Strength
	Have the timing for the transition of a patient from one care setting to another within the CP/VO been respected?	3.71	10	4.5	Strength	2.83	7	0.5	Faint Weakness
	Have there been multidisciplinary discussions about the patients' health conditions?	3.86	10	4.5	Strength	3.33	8	1.5	Strength
	Have structural changes been made to encourage social distancing?	3.29	8	1.5	Strength	3.33	8	1.5	Strength
	Have the services relating to non-deferrable diseases been guaranteed?	3.86	10	4.5	Strength	4.00	10	4.5	Strength
PROCEDURES AND RECOMMENDATIONS FOR HEALTHCARE	Have patient recommendations been made clear and visible?	4.00	10	4.5	Strength	4.00	10	4.5	Strength
	If yes, or enough, have they been respected?	3.71	10	4.5	Strength	3.33	8	1.5	Strength
	Have recommendations for relatives been made clear and visible?	4.00	10	4.5	Strength	4.00	10	4.5	Strength
	If yes, or enough, have they been respected?	3.71	10	4.5	Strength	3.17	8	1.5	Strength
	Have the recommendations been made clear and visible to healthcare professionals?	4.00	10	4.5	Strength	3.33	8	1.5	Strength
If yes, or enough, have they been respected?	3.43	9	3.0	Strength	3.33	8	1.5	Strength	
TRAINING, INFORMATION AND MANAGEMENT OF HEALTH WORKERS IN THE PANDEMIC ERA	Health care workers involved in PDTAs/VO have been trained on the dressing-doffing PPE procedures?	4.00	10	4.5	Strength	2.67	7	0.5	Faint Weakness
	The exposed health care personnel have been periodically subjected to rhino-pharyngeal swab to evaluate the possible positivity for SARS-CoV-2?	4.00	10	4.5	Strength	3.33	8	1.5	Strength
	Has the staff been equipped with PPE of modulated efficiency with respect to the professional risk to which they have been exposed?	3.86	10	4.5	Strength	3.17	8	1.5	Strength
	Have dirty paths and clean access paths to clinical departments been organized?	3.43	9	3.0	Strength	1.33	3	3.0	Strong Weakness
	Has the corporate anti-COVID vaccination program been performed using the employee booking portal?	4.00	10	4.5	Strength	0.83	2	4.0	Strong Weakness
Was the anti-COVID19 vaccination campaign, in the company/facility, preceded by an information campaign on the technical characteristics, methods of setting up and administering the vaccine?	4.00	10	4.5	Strength	2.83	7	0.5	Faint Weakness	

Figure 15. Cont.

B	ITEMS	CP 3				CP 4			
		CP 3 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category	CP 4 - MEAN SCORE	Classification scale	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	1.00	3	3.0	Strong Weakness	2.60	6	1.0	Faint Weakness
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	1.00	3	3.0	Strong Weakness	2.40	6	1.0	Faint Weakness
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	4.00	10	4.5	Strength	2.80	7	0.5	Faint Weakness
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	3.00	8	1.5	Strength	1.80	5	1.5	Faint Weakness
PATIENTS ACCESS TO CP/ UO	Do you use a pre-triage module during treatment?	4.00	10	4.5	Strength	2.80	7	0.5	Faint Weakness
	Are security measures taken?	4.00	10	4.5	Strength	3.60	9	3.0	Strength
	Are social distancing measures taken?	4.00	10	4.5	Strength	3.20	8	1.5	Strength
IMPACT ON TAKING OVER IN THE FOR OF NO-COVID PATIENTS	Has patient taking over been guaranteed within the pathway care anyway?	2.50	6	1.0	Faint Weakness	3.40	9	3.0	Strength
	Have the cancelled visits been rescheduled and recovered?	3.33	8	1.5	Strength	1.60	4	2.0	Strong Weakness
	Has remote monitoring been activated for patients who could not interrupt the treatment path (telemedicine)?	2.83	7	0.5	Faint Weakness	1.80	5	1.5	Faint Weakness
IMPACT ON TAKING OVER IN THE CP OF PATIENTS ALSO SARS COV-2 INFECTED	Have you treated COVID + patients in the pathway CP/UO?	1.17	3	3.0	Strong Weakness	1.20	3	3.0	Strong Weakness
	If yes or enough: in hospital in COVID wards?	0.17	1	5.0	Strong Weakness	0.00	1	5.0	Strong Weakness
	If yes or enough: by telephone counselling in COVID wards?	0.50	2	4.0	Strong Weakness	0.00	1	5.0	Strong Weakness
	If yes or enough: other	0.33	1	5.0	Strong Weakness	0.00	1	5.0	Strong Weakness
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	1.17	3	3.0	Strong Weakness	3.20	8	1.5	Strength
IMPACT OF THE COVID-19 PANDEMIC ON PATIENT MANAGEMENT	Have ad hoc organizational solutions been implemented for patient management with respect to the pre-pandemic era?	4.00	10	4.5	Strength	3.20	8	1.5	Strength
	Has therapeutic continuity been ensured within the pathway care?	3.67	10	4.5	Strength	3.80	10	4.5	Strength
	Have tele-assistance technological solutions been adopted for patient follow-up?	2.83	7	0.5	Faint Weakness	1.20	3	3.0	Strong Weakness
	Did all hospitalized patients repeat the SARS-Cov-2 test several times during the hospitalization period?	0.00	1	5.0	Strong Weakness	2.60	6	1.0	Faint Weakness
	Has the correct use of PPE (personal protective equipment) by healthcare professionals and patients been monitored?	4.00	10	4.5	Strength	3.40	9	3.0	Strength
STRUCTURAL AND ORGANIZATIONAL CHANGES OF THE CP/UO	Has the CP/UO remained unchanged from an organizational point of view?	3.83	10	4.5	Strength	1.80	5	1.5	Faint Weakness
	Have outpatient and/or surgical activities been guaranteed?	3.00	8	1.5	Strength	2.60	6	1.0	Faint Weakness
	Have the timing for the transition of a patient from one care setting to another within the CP/ UO been respected?	2.67	7	0.5	Faint Weakness	1.60	4	2.0	Strong Weakness
	Have there been multidisciplinary discussions about the patients' health conditions?	2.50	6	1.0	Faint Weakness	1.60	4	2.0	Strong Weakness
	Have structural changes been made to encourage social distancing?	4.00	10	4.5	Strength	3.20	8	1.5	Strength
	Have the services relating to non-deferrable diseases been guaranteed?	3.17	8	1.5	Strength	3.40	9	3.0	Strength
PROCEDURES AND RECOMMENDATIONS FOR HEALTHCARE	Have patient recommendations been made clear and visible?	4.00	10	4.5	Strength	3.00	8	1.5	Strength
	If yes, or enough, have they been respected?	3.83	10	4.5	Strength	3.20	8	1.5	Strength
	Have recommendations for relatives been made clear and visible?	4.00	10	4.5	Strength	3.20	8	1.5	Strength
	If yes, or enough, have they been respected?	4.00	10	4.5	Strength	3.40	9	3.0	Strength
	Have the recommendations been made clear and visible to healthcare professionals?	4.00	10	4.5	Strength	3.20	8	1.5	Strength
	If yes, or enough, have they been respected?	4.00	10	4.5	Strength	3.20	8	1.5	Strength

Figure 15. Cont.

TRAINING, INFORMATION AND MANAGEMENT OF HEALTH WORKERS IN THE PANDEMIC ERA	Health care workers involved in PDTAs/UO have been trained on the dressing-doffing PPE procedures?	4.00	10	4.5	Strength	3.80	10	4.5	Strength
	The exposed health care personnel have been periodically subjected to rhino-pharyngeal swab to evaluate the possible positivity for SARS-CoV-2?	4.00	10	4.5	Strength	3.60	9	3.0	Strength
	Has the staff been equipped with PPE of modulated efficiency with respect to the professional risk to which they have been exposed?	3.83	10	4.5	Strength	3.80	10	4.5	Strength
	Have dirty paths and clean access paths to clinical departments been organized?	0.00	1	5.0	Strong Weakness	3.40	9	3.0	Strength
	Has the corporate anti-COVID vaccination program been performed using the employee booking portal?	4.00	10	4.5	Strength	2.00	5	1.5	Faint Weakness
	Was the anti-COVID19 vaccination campaign, in the company/facility, preceded by an information campaign on the technical characteristics, methods of setting up and administering the vaccine?	4.00	10	4.5	Strength	2.60	6	1.0	Faint Weakness

Figure 15. Summary of the results regarding all the items of the four analyzed CPs. (A) Results of CP1 and CP2. (B) Results of CP3 and CP4.

For CP1 (hereditary breast–ovarian cancers CP), an index of 72.9% was calculated in the deeper analysis (Figure 10A), and 84.9% in the shallower one (Figure 10E), reaching a “very high” range in both cases. For CP2 (autism spectrum disorders CP), 61.9% was calculated in the deeper analysis (Figure 10B), and 63.6% in the shallower one (Figure 10F), reaching a “good” range in both cases. For CP3 (diabetes CP) 62.0% was calculated in the deeper analysis (Figure 10C), and 66.7% in the shallower one (Figure 10G), reaching a “good” range in both cases. Lastly, for CP4 (heart failure CP), 52.6% was calculated in the deeper analysis (Figure 10D), and 37.5% in the shallower one (Figure 10H), reaching a “null” range in both cases.

From the Figures (especially Figure 14), it is possible to notice the following:

- For all four analyzed CPs, Questionnaire Section 4 (“Impact on the treatment of patients also SARS-CoV-2 infected in the CPs”) is identified as a strong weakness;
- Both Questionnaire Section 1 (“Context analysis”) and Questionnaire Section 3 (“Impact on the treatment of non-COVID patients in the CPs”) are identified as a faint weakness for CP2, CP3, and CP4;
- Questionnaire Section 5 (“Impact of the COVID-19 pandemic on patient management”) is identified as a faint weakness for CP3 and CP4;
- Questionnaire Section 6 (“Structural and organizational changes of the CP/OU”) is identified as a faint weakness only for CP4;
- Questionnaire Section 8 (“Training, information, and management of health workers in the pandemic era”) is identified as a faint weakness only for CP2.

3.3. Single Wards

For Ward 1 of CP1 (corresponding to OUC Medical Genetics), the deeper analysis (Figure 11A) registers a performance index of 68.6%, whereas the shallower one (Figure 11B) registers an index of 83.6%, reaching a “very high” range in both cases.

For Ward 2 of CP2 (corresponding to OUC Mental Health Center H1–H3), the deeper analysis (Figure 11C) registers a performance index of 51.0%, whereas the shallower one (Figure 11D) registers an index of 65.2%, reaching a “null” and a “good” range respectively.

For Ward 3 of CP3 (corresponding to OUS Primary Care Districts C and D), the deeper analysis (Figure 11E) registers a performance index of 60.0%, whereas the shallower one (Figure 11F) registers an index of 75.0%, reaching a “good” and a “high” range, respectively.

For Ward 4 of CP4 (corresponding to OUD Shock and Trauma), the deeper analysis (Figure 11G) registers a performance index of 63.6%, whereas the shallower one (Figure 11H) registers an index of 79.4%, reaching a “high” and a “very high” range, respectively.

Figures 16 and 17 report the mean scores obtained with the survey, the priority scores inserted into the NGSAs, and the category. For all four wards analyzed, Questionnaire Section 4 (“Impact on the treatment of patients also SARS-CoV-2 infected in the CPs”) is identified as a strong weakness, and, for Ward 2 CP2, also Questionnaire Section 8 (“Training, information and management of health workers in the pandemic era”) is identified as a strong weakness.

ITEMS	Ward 1 CP 1			Ward 2 CP 2			Ward 3 CP 3			Ward 4 CP 4		
	SCORE	PRIORITY SCORE	Category	SCORE	PRIORITY SCORE	Category	SCORE	PRIORITY SCORE	Category	SCORE	PRIORITY SCORE	Category
SECTION 1 MEAN SCORE	3.00	1.5	Strength	3.25	1.5	Strength	2.25	1.0	Faint Weakness	3.00	1.5	Strength
SECTION 2 MEAN SCORE	3.67	4.5	Strength	4.00	4.5	Strength	4.00	4.5	Strength	2.67	0.5	Faint Weakness
SECTION 3 MEAN SCORE	4.00	4.5	Strength	3.33	1.5	Strength	3.33	1.5	Strength	3.00	1.5	Strength
SECTION 4 MEAN SCORE	0.20	5.0	Strong Weakness	0.20	5.0	Strong Weakness	0.20	5.0	Strong Weakness	1.00	3.0	Strong Weakness
SECTION 5 MEAN SCORE	3.00	1.5	Strength	3.00	1.5	Strength	3.00	1.5	Strength	3.20	1.5	Strength
SECTION 6 MEAN SCORE	4.00	4.5	Strength	3.17	1.5	Strength	3.67	4.5	Strength	3.50	3.0	Strength
SECTION 7 MEAN SCORE	4.00	4.5	Strength	4.00	4.5	Strength	4.00	4.5	Strength	3.67	4.5	Strength
SECTION 8 MEAN SCORE	4.00	4.5	Strength	1.33	3.0	Strong Weakness	3.33	1.5	Strength	3.33	1.5	Strength

Figure 16. Summary of the results regarding all the Questionnaire Sections of the four wards analyzed, one for each CP.

(A)

ITEMS	Ward 1 CP 1			Ward 2 CP 2			
	SCORE	PRIORITY SCORE	Category	SCORE	PRIORITY SCORE	Category	
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	3.00	1.5	Strength	4.00	4.5	Strength
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	2.00	1.5	Faint Weakness	3.00	1.5	Strength
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	4.00	4.5	Strength	3.00	1.5	Strength
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	3.00	1.5	Strength	3.00	1.5	Strength
PATIENTS ACCESS TO CP/ UO	Do you use a pre-triage module during treatment?	4.00	4.5	Strength	4.00	4.5	Strength
	Are security measures taken?	4.00	4.5	Strength	4.00	4.5	Strength
	Are social distancing measures taken?	3.00	1.5	Strength	4.00	4.5	Strength
IMPACT ON TAKING OVER IN THE FOR OF NO-COVID PATIENTS	Has patient taking over been guaranteed within the pathway care anyway?	4.00	4.5	Strength	4.00	4.5	Strength
	Have the cancelled visits been rescheduled and recovered?	4.00	4.5	Strength	3.00	1.5	Strength
	Has remote monitoring been activated for patients who could not interrupt the treatment path (telemedicine)?	4.00	4.5	Strength	3.00	1.5	Strength
IMPACT ON TAKING OVER IN THE CP OF PATIENTS ALSO SARS COV-2 INFECTED	Have you treated COVID + patients in the pathway CP/UO?	1.00	3.0	Strong Weakness	1.00	3.0	Strong Weakness
	If yes or enough: in hospital in COVID wards?	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness
	If yes or enough: by telephone counselling in COVID wards?	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness
	If yes or enough: other	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness

Figure 17. Cont.

IMPACT OF THE COVID-19 PANDEMIC ON PATIENT MANAGEMENT	Have ad hoc organizational solutions been implemented for patient management with respect to the pre-pandemic era?	4.00	4.5	Strength	4.00	4.5	Strength
	Has therapeutic continuity been ensured within the pathway care?	4.00	4.5	Strength	4.00	4.5	Strength
	Have tele-assistance technological solutions been adopted for patient follow-up?	3.00	1.5	Strength	3.00	1.5	Strength
	Did all hospitalized patients repeat the SARS-CoV-2 test several times during the hospitalization period?	4.00	4.5	Strength	0.00	5.0	Strong Weakness
	Has the correct use of PPE (personal protective equipment) by healthcare professionals and patients been monitored?	0.00	5.0	Strong Weakness	4.00	4.5	Strength
STRUCTURAL AND ORGANIZATIONAL CHANGES OF THE CP/UO	Has the CP/UO remained unchanged from an organizational point of view?	4.00	4.5	Strength	3.00	1.5	Strength
	Have outpatient and/or surgical activities been guaranteed?	4.00	4.5	Strength	3.00	1.5	Strength
	Have the timing for the transition of a patient from one care setting to another within the CP/UO been respected?	4.00	4.5	Strength	3.00	1.5	Strength
	Have there been multidisciplinary discussions about the patients' health conditions?	4.00	4.5	Strength	4.00	4.5	Strength
	Have structural changes been made to encourage social distancing?	4.00	4.5	Strength	2.00	1.5	Faint Weakness
	Have the services relating to non-deferrable diseases been guaranteed?	4.00	4.5	Strength	4.00	4.5	Strength
PROCEDURES AND RECOMMENDATIONS FOR HEALTHCARE	Have patient recommendations been made clear and visible?	4.00	4.5	Strength	4.00	4.5	Strength
	If yes, or enough, have they been respected?	4.00	4.5	Strength	4.00	4.5	Strength
	Have recommendations for relatives been made clear and visible?	4.00	4.5	Strength	4.00	4.5	Strength
	If yes, or enough, have they been respected?	4.00	4.5	Strength	4.00	4.5	Strength
	Have the recommendations been made clear and visible to healthcare professionals?	4.00	4.5	Strength	4.00	4.5	Strength
	If yes, or enough, have they been respected?	4.00	4.5	Strength	4.00	4.5	Strength
TRAINING, INFORMATION AND MANAGEMENT OF HEALTH WORKERS IN THE PANDEMIC ERA	Health care workers involved in PDTAs/UO have been trained on the dressing-doffing PPE procedures?	4.00	4.5	Strength	0.00	5.0	Strong Weakness
	The exposed health care personnel have been periodically subjected to rhino-pharyngeal swab to evaluate the possible positivity for SARS-CoV-2?	4.00	4.5	Strength	4.00	4.5	Strength
	Has the staff been equipped with PPE of modulated efficiency with respect to the professional risk to which they have been exposed?	4.00	4.5	Strength	3.00	1.5	Strength
	Have dirty paths and clean access paths to clinical departments been organized?	4.00	4.5	Strength	0.00	5.0	Strong Weakness
	Has the corporate anti-COVID vaccination program been performed using the employee booking portal?	4.00	4.5	Strength	0.00	5.0	Strong Weakness
	Was the anti-COVID19 vaccination campaign, in the company/facility, preceded by an information campaign on the technical characteristics, methods of setting up and administering the vaccine?	4.00	4.5	Strength	1.00	3.0	Strong Weakness

Figure 17. Cont.

(B)

	ITEMS	Ward 3 CP 3			Ward 4 CP 4		
		SCORE	PRIORITY SCORE	Category	SCORE	PRIORITY SCORE	Category
CONTEXT ANALYSIS	During the COVID-19 pandemic, did patients accept treatment in CP despite fears of contagion?	1.00	3.0	Strong Weakness	4.00	4.5	Strength
	Compared to the same period of the previous year, in the first pandemic event, did the number of accesses remain stable?	1.00	3.0	Strong Weakness	3.00	1.5	Strength
	Compared to the first pandemic period, during the second pandemic event the number of accesses to the pathways care remained stable?	4.00	4.5	Strength	3.00	1.5	Strength
	In pathway care during the first and second waves, has the volume of procedures remained stable compared to the same period of the previous year?	3.00	1.5	Strength	2.00	1.5	Faint Weakness
PATIENTS ACCESS TO CP/UO	Do you use a pre-triage module during treatment?	4.00	4.5	Strength	1.00	3.0	Strong Weakness
	Are security measures taken?	4.00	4.5	Strength	3.00	1.5	Strength
	Are social distancing measures taken?	4.00	4.5	Strength	4.00	4.5	Strength
IMPACT ON TAKING OVER IN THE FOR OF NO-COVID PATIENTS	Has patient taking over been guaranteed within the pathway care anyway?	3.00	1.5	Strength	4.00	4.5	Strength
	Have the cancelled visits been rescheduled and recovered?	4.00	4.5	Strength	3.00	1.5	Strength
	Has remote monitoring been activated for patients who could not interrupt the treatment path (telemedicine)?	3.00	1.5	Strength	2.00	1.5	Faint Weakness
IMPACT ON TAKING OVER IN THE CP OF PATIENTS ALSO SARS COV-2 INFECTED	Have you treated COVID + patients in the pathway CP/UO?	1.00	3.0	Strong Weakness	1.00	3.0	Strong Weakness
	If yes or enough: in hospital in COVID wards?	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness
	If yes or enough: by telephone counselling in COVID wards?	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness
	If yes or enough: other	0.00	5.0	Strong Weakness	0.00	5.0	Strong Weakness
	Have the clinical-assistance paths for COVID and NON_COVID patients been separated?	0.00	5.0	Strong Weakness	4.00	4.5	Strength
IMPACT OF THE COVID-19 PANDEMIC ON PATIENT MANAGEMENT	Have ad hoc organizational solutions been implemented for patient management with respect to the pre-pandemic era?	4.00	4.5	Strength	3.00	1.5	Strength
	Has therapeutic continuity been ensured within the pathway care?	4.00	4.5	Strength	4.00	4.5	Strength
	Have tele-assistance technological solutions been adopted for patient follow-up?	3.00	1.5	Strength	1.00	3.0	Strong Weakness
	Did all hospitalized patients repeat the SARS-Cov-2 test several times during the hospitalization period?	0.00	5.0	Strong Weakness	4.00	4.5	Strength
	Has the correct use of PPE (personal protective equipment) by healthcare professionals and patients been monitored?	4.00	4.5	Strength	4.00	4.5	Strength
STRUCTURAL AND ORGANIZATIONAL CHANGES OF THE CP/UO	Has the CP/UO remained unchanged from an organizational point of view?	4.00	4.5	Strength	3.00	1.5	Strength
	Have outpatient and/or surgical activities been guaranteed?	4.00	4.5	Strength	4.00	4.5	Strength
	Have the timing for the transition of a patient from one care setting to another within the CP/UO been respected?	3.00	1.5	Strength	3.00	1.5	Strength
	Have there been multidisciplinary discussions about the patients' health conditions?	3.00	1.5	Strength	3.00	1.5	Strength
	Have structural changes been made to encourage social distancing?	4.00	4.5	Strength	4.00	4.5	Strength
	Have the services relating to non-deferrable diseases been guaranteed?	4.00	4.5	Strength	4.00	4.5	Strength

Figure 17. Cont.

PROCEDURES AND RECOMMENDATIONS FOR HEALTHCARE	Have patient recommendations been made clear and visible?	4.00	4.5	Strength	3.00	1.5	Strength
	If yes, or enough, have they been respected?	4.00	4.5	Strength	3.00	1.5	Strength
	Have recommendations for relatives been made clear and visible?	4.00	4.5	Strength	4.00	4.5	Strength
	If yes, or enough, have they been respected?	4.00	4.5	Strength	4.00	4.5	Strength
	Have the recommendations been made clear and visible to healthcare professionals?	4.00	4.5	Strength	4.00	4.5	Strength
	If yes, or enough, have they been respected?	4.00	4.5	Strength	4.00	4.5	Strength
TRAINING, INFORMATION AND MANAGEMENT OF HEALTH WORKERS IN THE PANDEMIC ERA	Health care workers involved in PDTAs/UO have been trained on the dressing-doffing PPE procedures?	4.00	4.5	Strength	4.00	4.5	Strength
	The exposed health care personnel have been periodically subjected to rhino-pharyngeal swab to evaluate the possible positivity for SARS-CoV-2?	4.00	4.5	Strength	4.00	4.5	Strength
	Has the staff been equipped with PPE of modulated efficiency with respect to the professional risk to which they have been exposed?	4.00	4.5	Strength	4.00	4.5	Strength
	Have dirty paths and clean access paths to clinical departments been organized?	0.00	5.0	Strong Weakness	3.00	1.5	Strength
	Has the corporate anti-COVID vaccination program been performed using the employee booking portal?	4.00	4.5	Strength	1.00	3.0	Strong Weakness
	Was the anti-COVID19 vaccination campaign, in the company/facility, preceded by an information campaign on the technical characteristics, methods of setting up and administering the vaccine?	4.00	4.5	Strength	4.00	4.5	Strength

Figure 17. Summary of the results regarding all the items of the four wards analyzed, one for each CP. (A) Results of CP1 and CP2. (B) Results of CP3 and CP4.

For Ward 3 CP3 and for Ward 4 CP4, there is also a faint weakness in both Questionnaire Section 1 (“Context analysis”) and Questionnaire Section 2 (“Patients access to care pathways/operational units”), respectively.

4. Discussion

The main idea behind this work was to create a methodology for measuring the results of a survey used as an organizational analysis tool in the context of public health policy and to apply it to a previously performed survey regarding the adaptation of pathology-specific care pathways during the first two waves of the COVID-19 pandemic [14]. For this purpose, the Streetlight PRiority Swot system was constructed, allowing us to achieve two main results: establish which sectors of the analyzed organization should be addressed first in the strategic planning of the improvement actions (when deemed necessary to achieve an adequate level of care); and calculate a performance index, through the introduction of the NGSWOT Analysis, that allows us to establish the level of quality of the service offered, as it generates a percentage regarding the survey results as a whole. With the application of the SPRIS on the survey, it was possible to make a direct comparison between the four investigated CPs. For example, when referring to single items, it is possible to find that CP1 fared better than all the others (having a performance index of 72.9%), whereas CP4 fared so poorly that it reaches a “null” performance index (52.6%). Therefore, we can conclude that, regarding CP4, continuity of care was not properly guaranteed. This is a common problem reported in the literature, as the response to the COVID-19 pandemic was the focus on hospital care to prevent the health system from being overburdened during the “state of emergency”, overlooking the importance of primary care in guaranteeing the continuity of care, whilst also ensuring the same therapeutic and diagnostic quality [16,17], reducing outpatient visits number, having multidisciplinary meetings between physicians, and not

increasing the work of healthcare workers directly involved in facing the emergency [17]. These findings confirm those of the previous study regarding the COVID survey, as, taking into consideration the total score of each item reported in the previous study, CP1 had the highest score, and CP4 had the lowest [14]. This is confirmed by the literature, as it has been reported that the continuity of oncological care [18–20] and all cardiology services (e.g., outpatient clinics, community services, and cardiac rehabilitation) sustained significant reductions [21]. It should be noted that, also in the pre-pandemic era, many studies have sought to identify predictive factors of hospitalization and death and have been based on data obtained from hospital admissions or hospital emergency departments. Instead, the sample selection based on primary care will ensure the inclusion of patients with a wide range of severity, thus improving the risk evaluation [22].

It was also possible to compare different UO/wards, both inside the same CP and between different CPs. Looking at the results, in fact, it can be said that, in the analyzed UO/wards, Ward 1 of CP1 has the best performance index, and Ward 2 of CP2 has the worst one (Figure 11). This is probably due to the fact that, regarding the continuity of care for patients affected by both DSA and SARS-CoV-2, the number of cases was small, and it was not necessary to create separate pathways and/or wards [14], whereas the continuity of oncological care was, in any case, guaranteed thanks to the use of protective devices, pre-triage of patients accessing the hospital, delay of non-urgent visits, and use of telemedicine for patients' follow-up, in addition to periodical rhino-pharyngeal swabs for SARS-CoV-2 testing in healthcare workers [18–20]. It is interesting, however, how the literature reports a gap in the knowledge of palliative care [23] and that a higher education leads to higher chances of survival in some typologies of cancer [24].

The most important element of the SPRIS system is that the first two Excel sheets (*Streetlight color system* and *Priority scores*) erase as much subjectivity as possible, considering that both the classification scales and the priority scores are given following a conversion table. In fact, even by the priority scores, it was already possible to know what areas are faring better than the others, and, therefore, looking at the analysis of the items of every CP, it is noticeable how CP1 has a better level of performance than the others and that CP4 did not manage to properly adapt in front of the pandemic, in contrast to the other three CPs. It is also noticeable how, no matter the type of analysis, Questionnaire Section 4 is always identified as a strong weakness, probably because CPs find their roots in the need for the care management of patients with a specific disease in specific settings, and, therefore, during the pandemic, patients with non-COVID-related illnesses, but SARS-CoV-2 positive, did not follow the specific CP, but were treated within the COVID wards. As a consequence, the SPRIS system identified this as a strong weakness, giving it a high priority score and putting it very high in the decisional matrix.

Moreover, other studies analyzed how their clinical pathways fared in front of the pandemic, considering their key role in reducing the length of stay (LoS) [25] and hospital complications and in improving communication between professionals and safety and quality of care [26], showing varying results. In fact, the first wave of the COVID-19 pandemic has led to a better organization of clinical activities and regular testing among healthcare practitioners, with better chances to grant patients' protection, underlining the need to develop new protocols for maintaining the good performance of the CPs that are already available [19,21]. This need is highlighted also by the fact that a break in the continuity of care management often leads to decreased general conditions of the patients and healthcare settings [16,27–30].

Since a different depth of the analysis can be chosen, it is possible to use a superficial analysis in the first place and only apply a deeper analysis to those UO/wards that require it at a later time in order to identify more precisely the issues that have to be addressed. However, it is noticeable how the superficial analysis is less precise and might underestimate or overestimate the problem; in fact, comparing the results of the analysis of the single Questionnaire Sections and those of all the items, a difference can be registered. In this instance, CP1, CP2, and CP3 are overestimated, as the performance indexes calculated

using the Questionnaire Sections are higher than the ones obtained using all the items (respectively 12.0, 1.7, and 4.7 points percentage higher, going from 84.9%, 63.6%, and 66.7% in the shallower analysis to 72.9%, 61.9%, and 62.0% in the deeper analysis), and CP4 is underestimated, as the performance index is about 15.1 points lower, registering 52.6% in the deeper analysis and 37.5% in the shallower one. However, going from a more superficial analysis to a deeper one, the range is always the same; in fact, CP1 remains in a “very high” range, CP2 and CP3 remain in a “good” range, and CP4 remains in a “null” range (Table 3).

Moreover, when we considered all the CPs together, the index was high in both cases, confirming that, even when using a bigger dataset, the more superficial analysis is less precise, underestimating the quality of the service.

This is confirmed also by the indexes calculated for the single wards, as Ward 1 of CP1 reaches a “very high” range in both cases; Ward 2 of CP2 reaches a “null” and a “good” range, respectively; Ward 3 of CP3 reaches a “good” and a “high” range, respectively; and, lastly, Ward 4 of CP4 reaches a “high” and a “very high” range, respectively.

The decision to create a single percentage that “summarizes” the findings of the survey, represented by the performance index, was taken with the idea of enhancing the availability of comparable data across countries and over time. In fact, in the literature, there is both a great difficulty in comparing different public health policies with each other [5,29–32] and a gap regarding the systematic surveillance of public health policies adopted by different states across multiple public health arenas and their evolution and impact on health outcomes [33].

In fact, by generating a single indicator of both the quality and the performance of the whole activity, it is possible to avoid an item-per-item comparison between two surveys, and, therefore, only between common indicators. As a consequence, not only it is a survey data analysis method that can be applied to any kind of survey whose aim is to check the quality of an activity or a service, but it also gives the provider the ability to compare services from different settings, even when using surveys with different items.

4.1. Limits of the Study

The authors are aware of some limits. Firstly, our data are quite limited, as they refer to the experience in one region and are not extendible to a national level [14]. In fact, the Italian National Health System (SSN) did not approach the pandemic as a united front, [34,35]. Secondly, at the moment, to our knowledge, there are not any studies in the literature that use survey data to generate a comparable index [36]; therefore, it was impossible to make a comparison.

Thirdly, the SPRIS system still lacks a method of standardization, and it did not undergo a validation process. In fact, the classification of the items into the three categories (strengths, faint weaknesses, and strong weaknesses) is arbitrary, as is the assignation of the priority score, even if the authors did their best to make the logic behind the scores as sound as possible. Moreover, the presence of multiple sheets and various formulas might be a barrier for users. Lastly, it is important to keep in mind that this system can be used in countries with universal healthcare coverage, given the different perspectives of private healthcare systems [5]. Moreover, the use of the performance index as the only indicator of quality of care may hide the fact that, even if the service taken into consideration appears to be adequate in comparison to others, it still falls short of what is attainable through the full application of current medical knowledge [4].

Nevertheless, it is our opinion that the SPRIS system is the first step toward managing to pool data regarding health policy in a meta-analysis.

4.2. Further Prospective Work

It must be considered that this is a new theme, and for this reason, it is true that it requires a more in-depth analysis, but it can be a starting point. It is our belief that, considering our results and the limits of this study, the SPRIS system should undergo a full

validation process, also in order to eliminate any arbitrary elements left in it. In any case, the SPRIS system needs multiple applications on other surveys, both on other CPs and on other health services, in order to validate our findings. Furthermore, multiple applications would allow the scientific community to pool together the data across countries and over time, finally allowing it to compare different public health policies with each other.

4.3. Application

The most important application of the SPRIS system is in the evaluation of the efficacy of the improving measures introduced in a service; by calculating the performance index the first time, the questionnaire is distributed (time zero), and then the performance index is recalculated when the questionnaire is handed out once again after implementing the eventual changes. If, on the second time, the performance index is higher than the first time, then the improving actions were correctly implemented.

Moreover, our index can be used in a direct comparison between different services or organization, allowing us to give to the directional board an immediate overview of the quality of the services, and recognizing with just a glance those that need more resources or those that require a deeper analysis in order to identify the issues that have to be addressed during the elaboration of the improvement actions.

5. Conclusions

The SPRIS system showed to be an easily constructed tool that satisfies the needs expressed in the literature regarding an objective and precise overview of a service for strategic planning in healthcare without the need to use complex statistical analysis. It allows users to transform both quality and managerial survey data into an intuitive decision-making matrix that not only identifies the weakness of the system but prioritizes them, which is, to our knowledge, the true innovation brought by this system. A great help in the construction of the SPRIS system as an intuitive decision-making matrix has been the use of the Likert scale; that was the first step towards the conversion of qualitative data into quantitative.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijerph19137806/s1>, Supplementary Material S1: Delphi-Like Method. Supplementary Material S2: COVID Survey and Survey Results. References [37–39] are cited in the supplementary materials.

Author Contributions: Conceptualization, M.P., P.F., S.R. and G.B.; methodology, M.P., S.R., L.B., V.B., F.M. and P.F.; validation, C.N., R.M. and L.B.; formal analysis, L.B., V.B., A.G. (Angela Gabriele), A.G. (Aldo Germani), S.P. and P.F.; investigation, M.P., R.M., A.G. (Angela Gabriele), F.M., C.B., S.P., A.G. (Aldo Germani), S.G. and G.C.; resources, P.A., M.P., R.M., A.G. (Angela Gabriele), F.M., C.B., S.P., A.G. (Aldo Germani), S.G. and G.C.; data curation, L.B. and V.B.; writing—original draft preparation, M.P. and L.B.; writing—review and editing, C.N.; visualization, L.B. and M.P.; supervision, P.A., C.N., G.B. and M.R.; project administration, M.P., G.B. and M.R.; funding acquisition, R.M. All authors have read and agreed to the published version of the manuscript.

Funding: The work was partially supported by PRIN 2017 (Prot. 2017HWTP2K) and Ateneo 2021 (RM12117A5DAF2FA8) to R. Mancini.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Sapienza University of Rome, Italy (RIF. CE 5773_2020, Prot. # 52SA_2020, and Prot. # 171SA_2020).

Informed Consent Statement: Not applicable.

Data Availability Statement: All relevant data can be found in the Supplementary Materials.

Acknowledgments: The authors would like to thank the Department of Social Sciences and Economics, “Sapienza” University of Rome, for the support and all the respondents for the time given to this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Hailemariam, M.; Bustos, T.; Montgomery, B.; Barajas, R.; Evans, L.B.; Drahota, A. Evidence-based intervention sustainability strategies: A systematic review. *Implement. Sci.* **2019**, *14*, 57. [[CrossRef](#)] [[PubMed](#)]
- Rao, G.N.; Philips, A.P.; Benegal, V. Costs, Prohibition, and Need for Responsive Public Health Evidence. *Indian J. Community Med.* **2020**, *45*, 381. [[CrossRef](#)] [[PubMed](#)]
- Scholte, M.; Van Dulmen, S.A.; Neeleman-Van der Steen, C.W.M.; Van der Wees, P.J.; Nijhuis-van der Sanden, M.W.G.; Braspenning, J. Data extraction from electronic health records (EHRs) for quality measurement of the physical therapy process: Comparison between EHR data and survey data. *BMC Med. Inform. Decis. Mak.* **2016**, *16*, 141. [[CrossRef](#)] [[PubMed](#)]
- Donabedian, A. Evaluating the quality of medical care. *Milbank Q.* **2005**, *83*, 691–729. [[CrossRef](#)] [[PubMed](#)]
- Orton, L.; Lloyd-Williams, F.; Taylor-Robinson, D.; O’Flaherty, M.; Capewell, S. The Use of Research Evidence in Public Health Decision Making Processes: Systematic Review. *PLoS ONE* **2011**, *6*, e21704. [[CrossRef](#)] [[PubMed](#)]
- Rudolf, K. Evidence and policy: Interpreting the Delphic oracle. *J. R. Soc. Med.* **2003**, *96*, 429–431. [[CrossRef](#)]
- Gallè, F.; Sabella, E.A.; Roma, P.; Ferracuti, S.; Da Molin, G.; Diella, G.; Montagna, M.T.; Orsi, G.B.; Liguori, G.; Napoli, C. Knowledge and Lifestyle Behaviors Related to COVID-19 Pandemic in People over 65 Years Old from Southern Italy. *Int. J. Environ. Res. Public Health* **2021**, *18*, 10872. [[CrossRef](#)]
- Li, A.H.; Thomas, S.M.; Farag, A.; Duffett, M.; Garg, A.X.; Naylor, K.L. Quality of Survey Reporting in Nephrology Journals: A Methodologic Review. *Clin. J. Am. Soc. Nephrol.* **2014**, *9*, 2089–2094. [[CrossRef](#)]
- Giraldi, G.; Montesano, M.; Napoli, C.; Frati, P.; La Russa, R.; Santurro, A.; Scopetti, M.; Orsi, G.B. Healthcare-Associated Infections Due to Multidrug-Resistant Organisms: A Surveillance Study on Extra Hospital Stay and Direct Costs. *Curr. Pharm. Biotechnol.* **2019**, *20*, 643–652. [[CrossRef](#)]
- Gupta, B.; Ahluwalia, P. Need for a central survey-based registry-for effective conduct of survey-based medical research. *Indian J. Anaesth.* **2021**, *65*, 768–770. [[CrossRef](#)]
- Puhan, M.A.; Soesilo, I.; Guyatt, G.H.; Schünemann, H.J. Combining scores from different patient reported outcome measures in meta-analyses: When is it justified? *Health Qual. Life Outcomes* **2006**, *4*, 94. [[CrossRef](#)] [[PubMed](#)]
- Anoke, S.C.; Mwai, P.; Jeffery, C.; Valadez, J.J.; Pagano, M. Comparing two survey methods of measuring health-related indicators: Lot Quality Assurance Sampling and Demographic Health Surveys. *Trop. Med. Int. Health* **2015**, *20*, 1756–1770. [[CrossRef](#)] [[PubMed](#)]
- Chan, M.; Kazatchkine, M.; Lob-Levyt, J.; Obaid, T.; Schweizer, J.; Sidibe, M.; Veneman, A.; Yamada, T. Meeting the Demand for Results and Accountability: A Call for Action on Health Data from Eight Global Health Agencies. *PLoS Med* **2010**, *7*, e1000223. [[CrossRef](#)] [[PubMed](#)]
- Piane, M.; Bianco, L.; Mancini, R.; Fornelli, P.; Gabriele, A.; Medici, F.; Battista, C.; Greco, S.; Croce, G.; Franceschetti, L.; et al. Impact of the COVID-19 Pandemic on Clinical Pathways for Non-SARS-CoV-2 Related Diseases in the Lazio Region, Italy. *Int. J. Environ. Res. Public Health* **2022**, *19*, 635. [[CrossRef](#)] [[PubMed](#)]
- Drinkwater, B.L. A comparison of the direction-of-perception technique with the Likert method in the measurement of attitudes. *J. Soc. Psychol.* **1965**, *67*, 189–196. [[CrossRef](#)] [[PubMed](#)]
- Beran, D.; Perone, S.A.; Perolini, M.C.; Francois, C.; Chopard, P.; Haller, D.M.; Bausch, F.J.; Maisonneuve, H.; Perone, N.; Gastaldi, G. Beyond the virus: Ensuring continuity of care for people with diabetes during COVID-19. *Prim. Care Diabetes* **2021**, *15*, 16–17. [[CrossRef](#)]
- Capalbo, C.; Aceti, A.; Simmaco, M.; Bonfini, R.; Rocco, M.; Ricci, A.; Napoli, C.; Rocco, M.; Alfonsi, V.; Teggi, A.; et al. The Exponential Phase of the COVID-19 Pandemic in Central Italy: An Integrated Care Pathway. *Int. J. Environ. Res. Public Health* **2020**, *17*, 3792. [[CrossRef](#)]
- Indini, A.; Aschele, C.; Cavanna, L.; Clerico, M.; Daniele, B.; Fiorentini, G.; Fioretto, L.; Giordano, M.; Montesarchio, V.; Ortega, C.; et al. Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: A nationwide Italian survey. *Eur. J. Cancer* **2020**, *132*, 17–23. [[CrossRef](#)]
- Indini, A.; Pinotti, G.; Artioli, F.; Aschele, C.; Bernardi, D.; Butera, A.; Defraia, E.; Fasola, G.; Gamucci, T.; Giordano, M.; et al. Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. *Eur. J. Cancer* **2021**, *148*, 112–116. [[CrossRef](#)]
- Murriss, F.; Huchon, C.; Zilberman, S.; Dabi, Y.; Phalippou, J.; Canlorbe, G.; Ballester, M.; Gauthier, T.; Avigdor, S.; Cirier, J.; et al. Impact of the first lockdown for coronavirus 19 on breast cancer management in France: A multicentre survey. *J. Gynecol. Obstet. Hum. Reprod.* **2021**, *50*, 102166. [[CrossRef](#)]
- Fersia, O.; Bryant, S.; Nicholson, R.; McMeeken, K.; Brown, C.; Donaldson, B.; Jardine, A.; Grierson, V.; Whalen, V.; Mackay, A. The impact of the COVID-19 pandemic on cardiology services. *Open Heart* **2020**, *7*, e001359. [[CrossRef](#)] [[PubMed](#)]
- García-Olmos, L.; Rodríguez-Salvanés, F.; Batlle-Pérez, M.; Aguilar-Torres, R.; Porro-Fernández, C.; García-Cabello, A.; Carmona, M.; Ruiz-Alonso, S.; Ruiz-Alonso, S.; Garrido-Elustondo, S.; et al. Development and validation of a risk stratification model for prediction of disability and hospitalisation in patients with heart failure: A study protocol. *BMJ Open* **2017**, *7*, e014840. [[CrossRef](#)] [[PubMed](#)]

23. Chen, I.H.; Kuo, S.F.; Lin, Y.K.; Huang, T.W. Knowledge of and Barriers to Palliative Care Perceived by Healthcare Providers before and after Promotion of the Patient Autonomy Act: A Cross-Sectional Study. *Int. J. Environ. Res. Public Health* **2022**, *19*, 3884. [[CrossRef](#)] [[PubMed](#)]
24. Vincerževskiene, I.; Jasilionis, D.; Donatas Austys, D.; Stukas, R.; Kaceniene, A.; Smailyte, G. Education predicts cervical cancer survival: A Lithuanian cohort study. *Eur. J. Public Health* **2017**, *27*, 421–424. [[CrossRef](#)] [[PubMed](#)]
25. Trimarchi, L.; Caruso, R.; Magon, G.; Odone, A.; Arrigoni, C. Clinical pathways and patient-related outcomes in hospital-based settings: A systematic review and meta-analysis of randomized controlled trials. *Acta Biomed* **2021**, *92*, e2021093. [[CrossRef](#)]
26. Centre for Policy on Ageing (CPA). The Effectiveness of Care Pathways in Health and Social Care. 2014. Available online: <http://www.cpa.org.uk/information/reviews/CPA-Rapid-Review-Effectiveness-of-care-pathways.pdf> (accessed on 18 June 2022).
27. Banerjee, M.; Chakraborty, S.; Pal, R. Diabetes self-management amid COVID-19 pandemic. *Diabetes Metab. Syndr.* **2020**, *14*, 351–354. [[CrossRef](#)]
28. Peric, S.; Stulnig, T.M. Diabetes and COVID-19: Disease-Management-People. *Wien Klin. Wochenschr.* **2020**, *132*, 356–361. [[CrossRef](#)]
29. Caggiano, G.; Napoli, C.; Coretti, C.; Lovero, G.; Scarafale, G.; De Giglio, O.; Montagna, M.T. Mold contamination in a controlled hospital environment: A 3-year surveillance in southern Italy. *BMC Infect. Dis.* **2014**, *14*, 595. [[CrossRef](#)]
30. Pasquarella, C.; Veronesi, L.; Castiglia, P.; Liguori, G.; Montagna, M.T.; Napoli, C.; Rizzetto, R.; Torre, I.; Masia, M.D.; Di Onofrio, V. Italian multicentre study on microbial environmental contamination in dental clinics: A pilot study. *Sci. Total Environ.* **2010**, *408*, 4045–4051. [[CrossRef](#)]
31. Iatta, R.; Napoli, C.; Borghi, E.; Montagna, M.T. Rare mycoses of the oral cavity: A literature epidemiologic review. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **2009**, *108*, 647–655. [[CrossRef](#)]
32. Masia, M.D.; Dettori, M.; Deriu, G.M.; Soddu, S.; Deriu, M.; Arghittu, A.; Azara, A.; Castiglia, P. Microbial Monitoring as a Tool for Preventing Infectious Risk in the Operating Room: Results of 10 Years of Activity. *Atmosphere* **2021**, *12*, 19. [[CrossRef](#)]
33. Macinko, J.; Silver, D. Improving State Health Policy Assessment: An Agenda for Measurement and Analysis. *Am. J. Public Health* **2012**, *102*, 1697–1705. [[CrossRef](#)] [[PubMed](#)]
34. Bosa, I.; Castelli, A.; Castelli, M.; Ciani, O.; Compagni, A.; Galizzi, M.M.; Garofano, M.; Ghislandi, S.; Giannoni, M.; Marini, G.; et al. Corona-regionalism? Differences in regional responses to COVID-19 in Italy. *Health Policy* **2021**, *125*, 1179–1187. [[CrossRef](#)]
35. Arghittu, A.; Dettori, M.; Dempsey, E.; Deiana, G.; Angelini, C.; Bechini, A.; Bertoni, C.; Boccalini, S.; Bonanni, P.; Cinquetti, S.; et al. Health Communication in COVID-19 Era: Experiences from the Italian VaccinarSi Network Websites. *Int. J. Environ. Res. Public Health* **2021**, *18*, 5642. [[CrossRef](#)] [[PubMed](#)]
36. Phadernrod, B.; Crowder, R.M.; Wills, G.B. Importance-Performance Analysis based SWOT analysis. *Int. J. Inf. Manag.* **2019**, *44*, 194–203. [[CrossRef](#)]
37. Dalkey, N.C. An experimental study of group opinion: The Delphi method. *Futures* **1969**, *1*, 408–426. [[CrossRef](#)]
38. Niederberger, M.; Spranger, J. Delphi Technique in Health Sciences: A Map. *Front. Public Health* **2020**, *8*, 457. [[CrossRef](#)]
39. Escoffery, C.; Lebow-Skelley, E.; Udelson, H.; Böing, E.A.; Wood, R.; Fernandez, M.E.; Mullen, P.D. A scoping study of frameworks for adapting public health evidence-based interventions. *TBM* **2019**, *9*, 1–10. [[CrossRef](#)]